Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA. METHODS: Data were pool...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ann Rheum Dis
Hoofdauteurs: Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Thirunavukkarasu, Krishan, DeMasi, Ryan, Geier, Jamie, Kwok, Kenneth, Wang, Lisy, Riese, Richard, Wollenhaupt, Jürgen
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2017
Onderwerpen:
Clinical and Epidemiological Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5530353/
https://ncbi.nlm.nih.gov/pubmed/28143815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-210457
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items